20 mg/kg TRU-016 + Rituximab
16009
Phase 1 mab terminated
Quick answer
20 mg/kg TRU-016 + Rituximab for Chronic Lymphocytic Leukemia is a Phase 1 program (mab) at Aptevo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aptevo Therapeutics
- Indication
- Chronic Lymphocytic Leukemia
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated